News & Events

Results of Operations and Financial Condition.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (d) On April 10, 2026, the Board of Directors (the “Board”) of Humana Inc. (the “Company”) expanded its number of authorized directors from ten to eleven and elected Robert S. Field as a director of the Company, in each case effective immediately following the adjournment of the Humana Inc. 2026 Annual Meeting of Stockholders on April 16, 2026. The…

Entry into a Material Definitive Agreement. Underwriting Agreement On March 5, 2026, Humana Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, Mizuho Securities USA LLC, Truist Securities, Inc. and Wells Fargo Securities, LLC, as representatives of the several underwriters (together, the “Underwriters”), pursuant to which the Company agreed to issue and sell to the Underwriters $1.0 billion aggre…

Creation of a Direct Financial Obligation or an Obligation Under an Off-Balance Sheet Arrangement of a Registrant. The information required by

Regulation FD Disclosure. Members of Humana Inc.’s (the “Company”) senior management team are scheduled to meet with investors and analysts at various meetings between March 2, 2026 and March 31, 2026. During these meetings, the Company intends to reaffirm its guidance of at least $8.89 in diluted earnings per common share (“EPS”) or at least $9.00 in adjusted earnings per common share (“Adjusted EPS”), in each case for the year ending December 31, 2026 (“FY 2026”). This guidance is consisten…

Results of Operations and Financial Condition.

Regulation FD Disclosure. Members of Humana Inc.’s (the “Company”) senior management team are scheduled to meet with investors and analysts at various meetings between December 1, 2025 and December 31, 2025. During these meetings, the Company intends to reaffirm its guidance of approximately $12.26 in diluted earnings per common share (“EPS”) or approximately $17.00 in adjusted earnings per common share (“Adjusted EPS”), in each case for the year ending December 31, 2025 (“FY 2025”). This gui…

Regulation FD Disclosure. Supplementary Audio Commentary Supplementary audio commentary from Humana’s President and Chief Executive Officer, Jim Rechtin, may be accessed via Humana’s Investor Relations page at https://humana.gcs-web.com/. 2026 Medicare Advantage Star Ratings Based on preliminary 2026 Medicare Advantage (MA) Star Ratings data provided by the Centers for Medicare and Medicaid Services (CMS), which was inadvertently accessible on CMS Plan Finder for a period of time on October 1…

Regulation FD Disclosure. Members of Humana Inc.’s (the “Company”) senior management team are scheduled to meet with investors and analysts at various meetings between September 1, 2025 and September 30, 2025. During these meetings, the Company intends to reaffirm its guidance of approximately $13.77 in diluted earnings per common share (“EPS”) or approximately $17.00 in adjusted earnings per common share (“Adjusted EPS”), in each case for the year ending December 31, 2025 (“FY 2025”). This g…

Regulation FD Disclosure. Members of Humana Inc.’s (the “Company”) senior management team are scheduled to meet with investors and analysts at various meetings between June 2, 2025 and June 30, 2025. During these meetings, the Company intends to reaffirm its guidance of approximately $14.68 in diluted earnings per common share (“EPS”) or approximately $16.25 in adjusted earnings per common share (“Adjusted EPS”), in each case for the year ending December 31, 2025 (“FY 2025”). This guidance is…

Creation of a Direct Financial Obligation or an Obligation Under an Off-Balance Sheet Arrangement of a Registrant. The information described above under

Entry into a Material Definitive Agreement. On May 30, 2025, Humana Inc. (the “Company”) entered into a $5.0 billion unsecured revolving credit agreement with the several banks and other financial institutions from time to time parties thereto, JPMorgan Chase Bank, N.A. as Agent, Bank of America, N.A. as the Syndication Agent, Citibank, N.A., Goldman Sachs Bank USA, PNC Bank National Association, U.S. Bank, National Association and Wells Fargo Securities, LLC, as Documentation Agents, and JPM…

Regulation FD Disclosure. Members of Humana Inc.’s (the “Company”) senior management team are scheduled to meet with investors and analysts at various meetings between March 3, 2025 and March 31, 2025. During these meetings, the Company intends to reaffirm its guidance of approximately $15.88 in diluted earnings per common share (“EPS”) or approximately $16.25 in adjusted earnings per common share (“Adjusted EPS”), in each case for the year ending December 31, 2025 (“FY 2025”). This guidance…

Regulation FD Disclosure. Based on preliminary 2025 Medicare Advantage (MA) Star Ratings data provided by the Centers for Medicare and Medicaid Services (CMS), which became available in CMS Plan Finder as of October 1, 2024, Humana Inc. (“the Company”) has approximately 1.6 million, or 25%, of its members currently enrolled in plans rated 4 stars and above for 2025, a reduction from 94% in 2024. A significant driver of these results was contract H5216 decreasing to a 3.5-star rating from a 4.…

Regulation FD Disclosure. Members of Humana Inc.’s (the “Company”) senior management team are scheduled to meet with investors and analysts at industry conferences and various other meetings between September 3, 2024 and September 30, 2024. During these conferences and meetings, the Company intends to reaffirm its guidance of approximately $12.81 in diluted earnings per common share (“EPS”) or approximately $16.00 in adjusted earnings per common share (“Adjusted EPS”), in each case for the ye…

Regulation FD Disclosure. Members of Humana Inc.’s (the “Company”) senior management team are scheduled to meet with investors and analysts between June 3, 2024 and June 28, 2024. During these meetings, the Company intends to reaffirm its guidance of approximately $13.93 in diluted earnings per common share (“EPS”) or approximately $16.00 in adjusted earnings per common share (“Adjusted EPS”), in each case for the year ending December 31, 2024 (“FY 2024”). This guidance is consistent with the…

Regulation FD Disclosure. Members of Humana Inc.’s (the “Company”) senior management team are scheduled to meet with investors and analysts at an industry conference and various other meetings between March 5, 2024 and March 31, 2024. During these meetings, the Company intends to reaffirm its guidance of approximately $14.87 in diluted earnings per common share (“EPS”), or approximately $16.00 in adjusted earnings per common share (“Adjusted EPS”), in each case for the year ending December 31…

Regulation FD Disclosure. On Wednesday, January 31, 2024, after the stock market closed, the Centers for Medicare and Medicaid Services (CMS) issued its preliminary 2025 Medicare Advantage and Part D payment rates and proposed policy changes (collectively, the Advance Notice). CMS has invited public comment on the Advance Notice before publishing final rates on April 1, 2024 (the Final Notice). In the Advance Notice, CMS estimates Medicare Advantage plans across the sector will, on average, e…

Regulation FD Disclosure. 2024 Individual Medicare Advantage Enrollment Based on the results of the annual election period (AEP), Humana Inc. (the “Company”) now expects individual Medicare Advantage (MA) growth of approximately 100,000 members for the year ending December 31, 2024, representing 1.8 percent growth over its membership as of December 31, 2023 of approximately 5.4 million members, compared to its previous commentary of ‘at or slightly above industry average growth’. The Company’…

Results of Operations and Financial Condition.

Regulation FD Disclosure. Members of Humana Inc.’s (the “Company”) senior management team are scheduled to meet with investors and analysts at various meetings between December 1, 2023 and December 31, 2023. During these meetings, the Company intends to reaffirm its guidance of at least $26.31 in diluted earnings per common share (“EPS”) or at least $28.25 in adjusted earnings per common share (“Adjusted EPS”), in each case for the year ending December 31, 2023 (“FY 2023”). This guidance is c…

Regulation FD Disclosure. Members of Humana Inc.’s (the “Company”) senior management team are scheduled to meet with investors and analysts at industry conferences and various other meetings between September 6, 2023 and September 30, 2023. During these conferences and meetings, the Company intends to reaffirm its guidance of at least $26.91 in diluted earnings per common share (“EPS”) or at least $28.25 in adjusted earnings per common share (“Adjusted EPS”), in each case for the year ending…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (e) On August 17, 2023, the Board of Directors (the “Board”) of Humana Inc. (the “Company”), upon the recommendation of the Organization & Compensation Committee (the “Committee”) of the Board as advised by the Committee’s independent compensation consultant, approved the following revised schedule for non-employee director compensation, effective…

Regulation FD Disclosure. Members of Humana Inc.’s (the “Company”) senior management team are scheduled to meet with investors and analysts at various meetings between February 23, 2023, and March 31, 2023. During these meetings, the Company intends to address its prospects and performance. The date and time of presentations to investors are available via the Investor Relations calendar of events on the Company’s website at www.humana.com. Full Year 2023 Individual Medicare Advantage Enrollme…

Regulation FD Disclosure. Members of Humana Inc.’s (the “Company”) senior management team are scheduled to meet with investors and analysts at various times between January 9, 2023 and January 13, 2023. During these meetings, the Company intends to address its prospects and performance. The date and time of presentations to investors are available via the Investor Relations calendar of events on the Company’s website at www.humana.com. Full Year 2023 Individual Medicare Advantage Enrollment P…